Navigation Links
ThermoGenesis Announces China Customer Implements Cord Blood Products
Date:4/27/2011

RANCHO CORDOVA, Calif., April 27, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stems cells, said BoyaLife, a major stem cell bank in China, has become the largest operating cord blood banking organization in the country to commit to the implementation of its AXP® AutoXpress™ (AXP) and BioArchive® Systems used to process and store stem cells from cord blood.

Located in Wuxi, China, the BoyaLife stem cell bank opened two years ago, and is the first and only bank in China to be in accordance with international design standards of the American Blood Bank Association. BoyaLife is currently developing capacity to store over a million stem cell units.

BoyaLife is one of the Company's three cord blood products customers in China. Two other operators of cord blood stem cell banks in China, Beike Biotechnology (Beike) and Nanshan Memorial Medical Institute (Nanshan), have recently purchased AXP and BioArchive Systems from ThermoGenesis and will be installing them in the near future.

"With the addition of BoyaLife, we now have three of China's leading stem cell banks as customers for our cord blood devices. Industry analysts expect the China cord blood market to surpass the U.S. and reach $2 billion later this decade, of which we estimate our addressable market is 10-15%. We are pleased with our increasing presence in this rapidly expanding market and our ability to realize a key element of the Company's growth strategy--the expansion of our offerings into new and potential high-growth markets," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.

"As we implement our aggressive stem cell storage expansion initiative, we are pleased to be partnering with ThermoGenesis. They are providing leading-edge technology to the cord blood market and with the forecast for rapid growth in cord blood collections in China, we look forward to working with them in capitalizing on the market opportunity," said Dr. Xian-Chun Xu, Chairman and Chief Executive Officer of BoyaLife.

About BoyaLife

BoyaLife Inc. (www.boyalife.com), is a leading Chinese biopharmaceutical company applying cutting edge technologies in stem cells preservation and developing novel therapies for human diseases. BoyaLife is currently developing capacity to store 1.5 million stem cell units, making it the largest bank in China.  

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
2. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
3. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
4. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
5. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
6. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
7. ThermoGenesis Provides Update on Fiscal 2009 Results
8. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
9. ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall
10. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
11. ThermoGenesis Presentation at Rodman & Renshaw Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... ISTANBUL , June 9, 2016  Perkotek an innovation leader in attendance control ... to seamlessly log work hours, for employers to make sure the right employees are ... Logo - http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):